Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by William Blair

William Blair assumed coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research report issued on Wednesday, Briefing.com reports. The brokerage set an “outperform” rating on the stock.

Several other research analysts have also issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price on the stock. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $6.75.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $3.13 on Wednesday. The stock has a fifty day moving average of $4.24 and a 200-day moving average of $3.84. The stock has a market capitalization of $224.33 million, a P/E ratio of -1.61 and a beta of 1.85. Zentalis Pharmaceuticals has a 52 week low of $1.21 and a 52 week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). Equities research analysts forecast that Zentalis Pharmaceuticals will post -2.14 earnings per share for the current fiscal year.

Insider Activity at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters acquired 4,335,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the purchase, the insider owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This represents a 32.09% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. 5AM Venture Management LLC acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $19,147,378. BlackRock Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $18,205,000. Ishara Investments LP acquired a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $1,782,000. Bank of America Corp DE acquired a new stake in shares of Zentalis Pharmaceuticals in the second quarter valued at approximately $5,406,000. Finally, Primecap Management Co. CA bought a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth $4,643,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to address biological mechanisms involved in tumor growth, resistance to treatment and disease progression.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral, selective WEE1 kinase inhibitor. The company is evaluating azenosertib in clinical studies involving solid tumors and hematologic malignancies, including ovarian cancer, uterine serous carcinoma and other cancers.